Sarepta Therapeutics Inc (SRPT)
Return on total capital
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 260,055 | 129,442 | 54,923 | 46,263 | -505,738 | -645,961 | -852,048 | -1,054,752 | -636,715 | -647,938 | -438,168 | -292,031 | -355,423 | -415,258 | -567,845 | -640,270 | -490,137 | -551,063 | -485,146 | -615,596 |
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 1,527,740 | 1,221,070 | 1,077,070 | 961,192 | 859,337 | 764,357 | 741,411 | 712,749 | 384,950 | 430,840 | 726,457 | 856,886 | 928,009 | 469,528 | 485,108 | 535,445 | 761,759 | 892,047 | 1,042,870 | 1,144,830 |
| Return on total capital | 17.02% | 10.60% | 5.10% | 4.81% | -58.85% | -84.51% | -114.92% | -147.98% | -165.40% | -150.39% | -60.32% | -34.08% | -38.30% | -88.44% | -117.06% | -119.58% | -64.34% | -61.78% | -46.52% | -53.77% |
December 31, 2024 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $260,055K ÷ ($—K + $1,527,740K)
= 17.02%
Sarepta Therapeutics Inc's return on total capital has shown a significant improvement in recent periods after consistently displaying negative values. The company experienced negative returns on total capital for the majority of the observation period, indicating that the company was not generating sufficient profits from the capital invested in its operations.
However, starting from the first quarter of 2024, Sarepta Therapeutics Inc managed to achieve positive returns on total capital. This improvement is a positive sign for the company, indicating that it has been able to generate adequate profits relative to the total capital employed. The trend of the return on total capital moving from negative to positive values suggests that the company may have enhanced its operational efficiency and profitability in recent quarters.
It is essential for Sarepta Therapeutics Inc to sustain this positive trend in its return on total capital to ensure continued financial health and sustainable growth in the future. Further analysis and monitoring of this ratio, along with other financial metrics, will be crucial in evaluating the company's overall performance and financial sustainability.
Peer comparison
Dec 31, 2024